Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Ixazomib in Waldenstrom Macroglobulinemia
NCT03506373Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Aug 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and ixazomib in Waldenstrom macroglobulinemia (WM), sponsored by Mayo Clinic. Primary endpoint: Complete Response Rate at 4 years. Started Aug 2018; status: terminated.
02
Drugs
ibrutinibixazomib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03506373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506373.